[go: up one dir, main page]

BRPI0406861A - Utilização de agente antimuscarìnico - Google Patents

Utilização de agente antimuscarìnico

Info

Publication number
BRPI0406861A
BRPI0406861A BR0406861-0A BRPI0406861A BRPI0406861A BR PI0406861 A BRPI0406861 A BR PI0406861A BR PI0406861 A BRPI0406861 A BR PI0406861A BR PI0406861 A BRPI0406861 A BR PI0406861A
Authority
BR
Brazil
Prior art keywords
antimuscarinic agent
present
dyspeptia
tolterodine
urgency
Prior art date
Application number
BR0406861-0A
Other languages
English (en)
Inventor
Barbara H Korberly
Susan M Danehower
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32771960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0406861(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Publication of BRPI0406861A publication Critical patent/BRPI0406861A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"UTILIZAçãO DE AGENTE ANTIMUSCARìNICO". A presente invenção refere-se a um método, de preferência um método para via oral, para se tratar distúrbios urinários, tais como uma bexiga instável ou superativa, minimizando simultaneamente as ocorrências de boca seca, dispepsia e diminuição de fluxo de lágrimas. Os métodos da invenção presente incluem administrar-se a um mamífero, de preferência um ser humano, uma dose eficaz farmaceuticamente de um agente antimuscarínico, tal como a tolterodina, quando for necessário, conseguindo-se um alívio sintomático da urgência e/ou da freq³ência.
BR0406861-0A 2003-01-22 2004-01-14 Utilização de agente antimuscarìnico BRPI0406861A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44169003P 2003-01-22 2003-01-22
PCT/IB2004/000169 WO2004064821A1 (en) 2003-01-22 2004-01-14 Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders

Publications (1)

Publication Number Publication Date
BRPI0406861A true BRPI0406861A (pt) 2006-01-03

Family

ID=32771960

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406861-0A BRPI0406861A (pt) 2003-01-22 2004-01-14 Utilização de agente antimuscarìnico

Country Status (17)

Country Link
US (2) US20060047007A1 (pt)
EP (1) EP1589958B2 (pt)
JP (1) JP2006515607A (pt)
KR (1) KR20050096147A (pt)
CN (1) CN1741796A (pt)
AT (1) ATE432070T1 (pt)
AU (1) AU2004206110A1 (pt)
BR (1) BRPI0406861A (pt)
CA (1) CA2514022C (pt)
DE (1) DE602004021233D1 (pt)
ES (1) ES2324712T5 (pt)
IL (1) IL169362A0 (pt)
MX (1) MXPA05007767A (pt)
PL (1) PL377995A1 (pt)
TW (1) TW200418447A (pt)
WO (1) WO2004064821A1 (pt)
ZA (1) ZA200505026B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046663A1 (en) 2003-11-04 2005-05-26 Shire Laboratories, Inc. Compositions of quaternary ammonium containing bioavailability enhancers
PT2210605T (pt) * 2003-11-04 2017-04-24 Tcd Royalty Sub Llc Formas de dosagem única diária de tróspio
ES2322148T3 (es) * 2004-08-11 2009-06-17 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias.
WO2007093824A1 (en) * 2006-02-13 2007-08-23 Summit Corporation Plc Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
WO2009019599A2 (en) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
WO2011109403A1 (en) * 2010-03-01 2011-09-09 Xenoport, Inc. Use of (3r)-4-{[(1s)-2-methyl-1- (2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
CA2259012C (en) 1996-07-19 2008-05-13 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
IL136294A (en) * 1998-08-27 2004-02-08 Pharmacia & Upjohn Ab Use of toltrodine, 5-hydroxy methyl metabolite or its resmat in the preparation of drugs for the treatment of unstable or overactive bladder
DE60021749T2 (de) * 1999-11-11 2006-04-20 Pfizer Health Ab Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung

Also Published As

Publication number Publication date
TW200418447A (en) 2004-10-01
MXPA05007767A (es) 2006-01-31
CA2514022A1 (en) 2004-08-05
IL169362A0 (en) 2007-07-04
CA2514022C (en) 2010-07-13
US20070155838A1 (en) 2007-07-05
ZA200505026B (en) 2006-07-26
AU2004206110A1 (en) 2004-08-05
EP1589958B1 (en) 2009-05-27
EP1589958B2 (en) 2012-04-11
EP1589958A1 (en) 2005-11-02
ES2324712T3 (es) 2009-08-13
CN1741796A (zh) 2006-03-01
WO2004064821A1 (en) 2004-08-05
JP2006515607A (ja) 2006-06-01
US20060047007A1 (en) 2006-03-02
PL377995A1 (pl) 2006-02-20
KR20050096147A (ko) 2005-10-05
DE602004021233D1 (de) 2009-07-09
ATE432070T1 (de) 2009-06-15
ES2324712T5 (es) 2012-06-08

Similar Documents

Publication Publication Date Title
MXPA04003866A (es) Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva.
KR960703009A (ko) 중추유래의 수면성 무호흡증 및 호흡곤란증의 치료를 위한 모다피닐의 사용
UY26693A1 (es) Una composición farmacéutica y procedimiento de tratamiento de enfermedades de disfunción cognitiva en un mamífero
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
SE9802073D0 (sv) New use
ATE277596T1 (de) Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
AU3846901A (en) Oral, nasal and pulmonary dosage formualtions of copolymer 1
MXPA03006439A (es) Metodo y composiciones novedosos para tratamiento local del mal del meniere, zumbido de oidos y/o perdida de oido.
EE05315B1 (et) Dapoksetiini v?i selle farmatseutiliselt vastuv?etava soola kasutamine ravimi valmistamiseks, mis on ette n„htud imetajal esineva seksuaalse funktsioonih„ire ravimiseks v?i m?jutamiseks
BRPI0406861A (pt) Utilização de agente antimuscarìnico
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
HK1024631A1 (en) Use of (+) mefloquine for the treatment of malaria
NO20013414D0 (no) Ny anvendelse av melagatran
AP1896A (en) The method of treating cancer
WO2022026622A3 (en) Treatment of viral diseases
CA2432177A1 (en) Drug for prevention and/or therapy of endometriosis
MXPA04001805A (es) Nueva forma de dosificacion oral de liberacion prolongada.
NO20042586L (no) Behandlingsfremgangsmate
RU2002105074A (ru) Способ лечения и профилактики развития гипертрофических и келоидных рубцов
WO2023104086A3 (en) Oral care compositions with hyaluronic acid
WO2002013825A8 (en) Novel pharmaceutical use of quinnoline derivatives
MXPA02007454A (es) Compuestos utiles para tratamiento o prevencion de una enfermedad mediada por el alfa-2b-adrenoceptor.
MD1898G2 (ro) Remediu dermatologic stabilizat pe bază de juglonă
WO1999048483A3 (en) (-)-phenylpropanolamine as a sympathomimetic drug
RU2006146071A (ru) Средство для устранения фактора циркуляторной дисфункции

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.